Publications by Dr Shelby Barnett - ePrints

Browsing publications by Dr Shelby Barnett.

Newcastle Authors	Title	Year
Professor Gareth Veal Dr Shelby Barnett	Utility of carboplatin therapeutic drug monitoring for the treatment of neonate and infant retinoblastoma patients in the United Kingdom	2024
Dr Shelby Barnett Dr Martin Galler Dr David Jamieson Professor Gareth Veal	Excessive vincristine exposure in a child being treated for acute lymphoblastic leukaemia with underlying Dubin–Johnson syndrome: a case report	2023
Dr Shelby Barnett Professor Deborah Tweddle Professor Gareth Veal	Generation of evidence-based carboplatin dosing guidelines for neonates and infants	2023
Dr Shelby Barnett Professor Gareth Veal	Physiologically-based pharmacokinetic model to predict doxorubicin and paclitaxel exposure in infants through breast milk	2023
Julie Errington Dr Shelby Barnett Professor Gareth Veal	Spontaneous fractures during 13-cis retinoic acid therapy for neuroblastoma	2023
Dr Shelby Barnett Professor Gareth Veal	A population pharmacokinetic modelling approach to unravel the complex pharmacokinetics of vincristine in children	2022
Dr Shelby Barnett Dr Vickyanne Carruthers Professor Deborah Tweddle Professor Gareth Veal	Clinical pharmacology of cytotoxic drugs in neonates and infants: providing evidence-based dosing guidance	2022
Dr Vickyanne Carruthers Dr Shelby Barnett Dr Tasnim Arif Professor Gareth Veal	Clinical utility of vinblastine therapeutic drug monitoring for the treatment of infantile myofibroma patients: A case series	2022
Dr Shelby Barnett Professor Gareth Veal	Perspectives and expertise in establishing a therapeutic drug monitoring programme for challenging childhood cancer patient populations	2022
Dr Shelby Barnett Professor Deborah Tweddle Professor Gareth Veal	Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients	2022
Dr Shelby Barnett Professor Gareth Veal	Over a decade of experience with carboplatin therapeutic drug monitoring in a childhood cancer setting in the United Kingdom	2021
Dr Shelby Barnett	PBPK Model of Coproporphyrin I: Evaluation of the Impact of SLCO1B1 Genotype, Ethnicity, and Sex on its Inter‐Individual Variability	2021
Dr Shelby Barnett Julie Errington Julieann Sludden Dr David Jamieson Professor Gareth Veal et al.	Pharmacokinetics and pharmacogenetics of cyclophosphamide in a neonate and infant childhood cancer patient population	2021
Dr Shelby Barnett	Comprehensive Evaluation of the Utility of 20 Endogenous Molecules as Biomarkers of OATP1B Inhibition Compared with Rosuvastatin and Coproporphyrin I	2019
Dr Shelby Barnett	Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B‐Mediated Drug–Drug Interactions Using Population Pharmacokinetic Modeling and Simulation	2018
Dr Shelby Barnett	In vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems	2016
Dr Shelby Barnett	Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues	2015